Usefulness of C-reactive protein in monitoring the severe community-acquired pneumonia clinical course
Open Access
- 28 August 2007
- journal article
- Published by Springer Nature in Critical Care
- Vol. 11 (4) , R92
- https://doi.org/10.1186/cc6105
Abstract
Background: The aim of the present study was to evaluate the C-reactive protein level, the body temperature and the white cell count in patients after prescription of antibiotics in order to describe the clinical resolution of severe community-acquired pneumonia. Methods: A cohort of 53 consecutive patients with severe community-acquired pneumonia was studied. The C-reactive protein levels, body temperature and white cell count were monitored daily. Results: By day 3 a C-reactive protein level 0.5 times the initial level was a marker of poor outcome (sensitivity, 0.91; specificity, 0.59). Patients were divided according to their C-reactive protein patterns of response to antibiotics, into fast response, slow response, nonresponse, and biphasic response. About 96% of patients with a C-reactive protein pattern of fast response and 74% of patients with a slow response pattern survived, whereas those patients with the patterns of nonresponse and of biphasic response had a mortality rate of 100% and 33%, respectively (P < 0.001). On day 3 of antibiotic therapy, a decrease in C-reactive protein levels by 0.31 or more from the previous day's level was a marker of good prognosis (sensitivity, 0.75; specificity, 0.85). Conclusion: Daily C-reactive protein measurement after antibiotic prescription is useful in identification, as early as day 3, of severe community-acquired pneumonia patients with poor outcome. The identification of the C-reactive protein pattern of response to antibiotic therapy was useful in the recognition of the individual clinical course, either improving or worsening, as well as the rate of improvement, in patients with severe community-acquired pneumonia.Keywords
This publication has 25 references indexed in Scilit:
- Contribution of C-Reactive Protein to the Diagnosis and Assessment of Severity of Community-Acquired PneumoniaChest, 2004
- Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trialThe Lancet, 2004
- C-reactive protein in the diagnosis of community-acquired pneumonia.The Brazilian Journal of Infectious Diseases, 2003
- C-Reactive Protein Levels Correlate With Mortality and Organ Failure in Critically Ill PatientsaChest, 2003
- C-reactive protein levels in community-acquired pneumoniaEuropean Respiratory Journal, 2003
- Hospitalized Community-acquired Pneumonia in the ElderlyAmerican Journal of Respiratory and Critical Care Medicine, 2002
- The pulmonary physician in critical care 3: Critical care management of community acquired pneumoniaThorax, 2002
- C-reactive protein: a valuable marker of sepsisIntensive Care Medicine, 2002
- BTS Guidelines for the Management of Community Acquired Pneumonia in Adults.Published by Korean Cancer Association ,2001
- Antimicrobial Treatment Failures in Patients with Community-acquired PneumoniaAmerican Journal of Respiratory and Critical Care Medicine, 2000